Monday, September 30, 2019

Ranitidine controversy: Which Indian pharma companies stand to lose?

Ranitidine controversy: Which Indian pharma companies stand to lose? NULL

from Moneycontrol Business News https://ift.tt/2nRJ8ks

No comments:

Post a Comment

Tariffs a temporary storm, structural reforms key for India: Arvind Sanger

Arvind Sanger of Geosphere Capital Management suggests a trade deal with the U.S. would benefit India by reducing market uncertainty and pro...